SuperworthAutolus Therapeutics price to book ratio AUTL
Market value divided by the book value of the company's net assets, since 2023.
- Today, Oct 23, 2026
- 5.5×
- 3-year median
- 1.9×
- Against its 3-year history
- 79th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 0.8× to 15.2×
- Peer median
- 5.0×
Autolus Therapeutics' price to book ratio is 5.5× as of Oct 23, 2026.
That is above its 3-year median of 1.9×, higher than on 79% of days in the last 3 years.
Over that time it ranged from 0.8× in Apr 2025 to 15.2× in Mar 2024.
The median for 4 biotech stocks of a similar size is 5.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 5.5× | 1.2× | 8.6× |
| 2025 | 1.7× | 0.8× | 1.8× |
| 2024 | 1.3× | 1.3× | 15.2× |
| 2023 | 6.2× | 3.3× | 6.2× |
Against its peers
Companies in Biotechnology nearest Autolus Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| AUTLAutolus Therapeutics | 5.5× |
| PLXProtalix BioTherapeutics | 2.9× |
| MGTXMeiraGTx | 4.1× |
| VCELVericel | 5.9× |
| ADMAAdma Biologics | 5.9× |
| Peer median | 5.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Autolus Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.